Auto-immune Hepatitis
Conditions
Keywords
autoantibodies, auto-immune hepatitis, prognosis, afrocaribbean population
Brief summary
Evaluate the proportion of seronegative auto-immune hepatitis and a possible relationship with the severity of the disease. Criteria of severity will be defined by corticodependance, corticoresistance and a severe form of the disease at diagnosis (cirrhosis or fulminant hepatitis). In case of predominant seronegative forms, other auto-antibodies related to this auto-immue hepatitis will be searched.
Detailed description
Evaluate the proportion of seronegative auto-immune hepatitis and a possible relationship with the severity of the disease. Criteria of severity will be defined by corticodependance, corticoresistance and a severe form of the disease at diagnosis (cirrhosis or fulminant hepatitis). In case of predominant seronegative forms, other auto-antibodies related to this auto-immue hepatitis will be searched. Patients from the Guadeloupean constitutive center of rare diseases (CCRD Filfoie) and from the Saint-Antoine hospital will be retrospectively analyzed, and new patients will be prospectively followed.
Interventions
OTHERblood sampling
For the study, a blood sample will be collected from the patient in order to do build up a serological library which will allow the search for rare autoAb whose interest has been demonstrated as prognostic factors of the disease.
Sponsors
Centre Hospitalier Universitaire de la Guadeloupe
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* \- Any patient over 18 years old * Patient followed at Hôpital Saint-Antoine or treated for HAI or in Guadeloupe within the framework of the CCRD Filfoie for an acute or chronic AIH under immunosuppressive treatment * Patient affiliate or beneficiary of a social security scheme * Free, informed and written consent signed by the patient and the investigator o
Exclusion criteria
- Patient under 18 years old * Patient not able to give his/her consent * Viral hepatitis: viruses A to E, Epstein-Barr virus, cytomegalovirus and herpes simplex virus * Isolated primary biliary cholangitis * Isolated primary sclerosing cholangitis * Drug-induced liver injury * Wilson disease * Alcoholic hepatitis * Hemochromatosis * Sickle cell disease and heart liver * Non-alcoholic steato-hepatitis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| histological rereading of seronegative AIH | Baseline | Percentage comparisons will be made by a chi-2 test or a Fischer test. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| assessment of the severity of the disease | 6 months, 12 months | \- Number of corticosteroid HAI defined by the maintenance of corticosteroid therapy\> 20mg / d beyond 6 months of treatment - Number of corticosteroid-resistant AIH. Percentage comparisons will be made by a chi-2 test or a Fischer test. |
| Constitution of a serotheque in order to search for other autoAb described as correlated to the severity of the AIH. | At inclusion | Constitution of a serotheque in order to search for other autoAb described as correlated to the severity of the AIH. |
Countries
France
Contacts
Primary ContactValérie SOTER, Promotion Unit manager
Backup ContactEunice NUBRET, Project manager
Outcome results
None listed